Search Results for “EC” – Page 59 – media

Opdivo Plus Yervoy Reduces the Risk of Colorectal Cancer Disease Progression or Death by 79% Versus Chemotherapy

Opdivo plus Yervoy shows promise in treating patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer. Image Credit: Adobe Stock Images/Crystal light The combination of Bristol Myers Squibb’s Opdivo (nivolumab) with Yervoy (ipilimumab) showed significant improvements in progression-free survival (PFS) as a first-line treatment for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)in the Phase III CheckMate -8HW trial. The combination produced a 79% reduction in the risk of disease progression or death compared to chemotherapy, according to the trial. “Patients with MSI-H/dMMR metastatic colorectal cancer are less likely to benefit from chemotherapy,” said Thierry Andre, MD, head of the medical oncology department, Sorbonne University, Hospital Saint-Antoine, Paris, France, in a press release. “An impressive improvement in PFS and sustained benefit beginning at three months was observed with nivolumab plus ipilimumab versus chemotherapy in this trial. These results demonstrate ...
- Source: https://www.pharmexec.com/authors/don-tracy-associate-editor
- 76
- January 24, 2024
Immune checkpoint inhibitor target found to promote skin cancer growth

Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating various types of cancer. But PD-1 functions can vary between different cell and cancer types, either promoting or suppressing disease progression. Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer, responds well to immune checkpoint inhibitor therapy. However, it was previously unknown if MCC cells express PD-1 themselves, and unclear how exactly cancer cell-intrinsic PD-1 contributes to tumor growth. A study led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, identified a new mechanism through which PD-1 promotes MCC progression. Through a series of experiments, the researchers demonstrated PD-1 expression on MCC cells in preclinical models and patient tumor samples. They found that MCC-PD-1 receptor binding to its ligands ...
- Source: drugdu
- 97
- January 23, 2024
RecA protein skips “unwinding” step in DNA repair

Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a dangling single-strand end into intact double strands, and repairing the break based on the undamaged sequence. They discovered that RecA finds where to put the single strand into the double helix without unwinding it by even a single turn. Their findings promise new directions in cancer research. Homologous recombination (HR) is a ubiquitous biochemical process shared across all living things, including animals, plants, fungi, and bacteria. As we go about our daily lives, our DNA is subjected to all kinds of environmental and internal stress, some of which can lead to breakage of both strands in the double helix. This can be disastrous, and lead to imminent cell death. Luckily, processes like HR are continuously repairing this damage. During HR, one of the two exposed ...
- Source: drugdu
- 180
- January 23, 2024
Pusan National University Announces Potential Breakthrough for Muscle Regeneration Using Nanotech

Pusan National University announced a potential breakthrough in muscle regeneration technology. Researchers at the university studied MXene nanoparticles (NP) in an attempt to better understand how these nanoparticles work. In a press release, the university details how a team of researchers used DNA sequencing on nanofibrous matrices which contained MXene NPs. The results revealed the genes and biological pathways that were activated by the NPs.This is considered a breakthrough because up until these findings, the specific mechanism these NPs used to promote muscles was unclear to researchers. Prior to this, MXene NPs were only shown in laboratory demonstrations to promote growth. The team of researchers includes associate professor Yun Hak Kim, professor Suck Won Hong, and professor Dong-Wook Han. Kim is from the Department of Anatomy and the Department of Biomedical Informatics, while Hong and Han are from the Department of Cogno-Mechatronics Engineering. MXene NPs could potentially be used in ...
- Source: drugdu
- 83
- January 23, 2024
Pfizer’s Talzenna recommended by NICE for advanced breast cancer

Pfizer’s Talzenna (talazoparib) has become the first targeted treatment to be recommended by the National Institute for Health and Care Excellence (NICE) to treat HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations. Patients eligible for the PARP inhibitor will have previously been treated with anthracycline or taxane chemotherapy, or both, unless these treatments are not suitable. Additionally, those with HR-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for this.NICE’s final draft guidance, which reverses its earlier draft decision not to recommend Talzenna for this patient population, follows Pfizer’s offer of an increased discount of the treatment.The agency estimates that 300 breast cancer patients, who would otherwise be limited to chemotherapy and best supportive care, will benefit from the new recommendation. Stefano Podesta, oncology lead at Pfizer UK, said: “[The] decision is an important milestone for eligible patients with advanced-stage breast ...
- Source: drugdu
- 84
- January 23, 2024
Biotech layoffs strike hard with PMV Pharma, Ikena, and Bayer sacking staff

Amidst a successful conclusion to the 2024 JP Morgan Healthcare Conference, biotech and pharma layoff numbers are on a consistent rise with PMV Pharmaceuticals and Ikena Oncology being the latest to follow pharma giant Bayer’s recent restructuring plans. PMV Pharmaceuticals plans to fire 30% of its workforce in a bid to free capital that will go towards the development of its lead tumour agnostic therapy PC14586.As per the New Jersey-based company, the strategic restructuring will extend PMV’s cash runway until the end of 2026 and will allow the company to focus on discovery research efforts and prioritise initiation of a Phase II clinical study of p53 reactivator PC14586 that is slotted for commencement in Q1 2024. The precision oncology company’s latest restructuring follows a March 2023 pipeline optimisation effort, in which the company announced that its WIP-1 inhibitor and R273H mutation-targeting programs had been shelved to drive the development of ...
- Source: drugdu
- 72
- January 23, 2024
Hai Zheng Pharmaceutical and Sinopharm Signed Strategic Cooperation Agreement on Retail Project

Hai Zheng Pharmaceutical (hereinafter referred to as “Hai Zheng Pharmaceutical”) signed a strategic cooperation agreement on retail project with Sinopharm Holdings Corporation (hereinafter referred to as “Sinopharm”) in Shanghai. (hereinafter referred to as “Sinopharm”) signed a strategic cooperation agreement on retail project in Shanghai, both parties will carry out in-depth cooperation in healthcare and retail channels, through the integration of the advantageous resources of both parties to maximize the synergistic effect, and to bring more personalized, convenient and efficient drug purchasing experience for the majority of patients to improve the level of service. At the meeting, HANHUI Pharmaceutical and Guozhong Quanzai introduced the company profiles and project plans of the two sides respectively, and launched in-depth exchanges and discussions on the strategic cooperation of the two sides’ retail projects. Chairman Shen Xinghu and his entourage also visited the corporate showroom in Sinopharm Building to understand the development history, business innovation ...
- Source: drugdu
- 71
- January 23, 2024
FastWave Medical kicks off first-in-human study of its IVL tech

FastWave Medical announced the successful completion of enrollment for its first-in-human study of its peripheral intravascular lithotripsy (IVL) system to treat calcified cardiovascular disease. Dr. Miguel Montero-Baker of Houston Methodist Hospital and the Hope Vascular & Podiatry Clinic and Dr. Venkatesh Ramaiah of HonorHealth Vascular Group and the Pulse Cardiovascular Institute successfully conducted the procedures with the hosting investigator, Dr. Antonio Muñoa. “I am excited to be part of the initial cases to evaluate FastWave’s peripheral IVL platform. Their team has rapidly developed an easy-to-use system to address existing technological gaps, marking a significant milestone in achieving the company’s near-term goals,” Montero-Baker said in a news release. Minneapolis-based FastWave’s IVL platform is meant to treat calcific artery disease by fracturing calcium deposits with a balloon catheter that deliversshock waves. The company says its peripheral IVL technology offers a user-friendly design with a deliverable, low-profile, rupture-resistant balloon. The system delivers durable ...
- Source: drugdu
- 121
- January 22, 2024
Ultrasensitive Molecular Diagnostic Tools Detect Asymptomatic Malaria

Malaria remains a significant cause of illness and death, particularly in low-income countries, striking hardest among young children and pregnant women. In 2022 alone, the World Health Organization reported 608,000 malaria deaths globally, with a staggering 95% of these occurring in the African region. A key challenge in controlling malaria, especially in endemic areas, is identifying and treating asymptomatic carriers of the disease. In response to this challenge, researchers have developed advanced diagnostic tools capable of detecting even minimal traces of malaria in individuals who carry the parasite but do not exhibit symptoms. A collaborative effort between scientists from the University of Washington (Seattle, WA, USA) and Med Biotech Laboratories (Kampala, Uganda) has led to significant advancements in malaria detection. The researchers observed that malaria parasite densities in the blood can suddenly fall below the detection threshold of traditional tests due to the evolving nature of the malaria pathogens. This ...
- Source: drugdu
- 158
- January 22, 2024
New Algorithm Detects and Identifies Novel Bacterial Organisms

Hospitals frequently encounter unknown germs, and identifying these pathogens is crucial for efficient bacterial infection treatment. Typically, medical laboratory analysis can identify these pathogens, but standard methods sometimes fall short, especially when dealing with unclassified bacterial species or those difficult to cultivate. Since 2014, a dedicated research team has been collecting and analyzing patient samples containing such elusive germs, leading to the discovery of over 30 new bacteria species, some linked to significant clinical infections. The team at the University of Basel (Basel, Switzerland) examined a total of 61 unidentified bacterial pathogens from various patient blood and tissue samples. These pathogens had previously eluded identification by conventional lab techniques like mass spectroscopy or partial bacterial genome sequencing. The researchers then employed a more recent method to sequence the complete genetic material of these bacteria. By comparing the genomes with known strains using an online tool, they identified 35 previously unknown ...
- Source: drugdu
- 128
- January 22, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.